Paula Martín-Climent

Ms. Paula Martín-Climent


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2023 in Cells
Verified
Journal Article
Open access
PDF file
IHIrati Hervás-Corpión
Irati Hervás-Corpión
JCJorge Navarro Calvo
Jorge Navarro Calvo
PMPaula Martín-Climent
Paula Martín-Climent
MIMarianela Iriarte_Gahete
Marianela Iriarte_Gahete
NGNoelia Geribaldi
Noelia Geribaldi
LVLuis M. Valor
Luis M. Valor
Glioblastoma (GB) is the most prevalent primary brain cancer and the most aggressive form of glioma because of its poor prognosis and high recurrence. To confirm the importance of epigenetics in glioma, we explored The Cancer Gene Atlas (TCGA) database and we found that several histone/DNA modifications and chromatin remodeling factors were affected at transcriptional and genetic levels in GB compared to lower-grade gliomas. We associated these alterations in our own cohort of study with a significant reduction in the bulk levels of acetylated lysines 9 and 14 of histone H3 in high-grade compared to low-grade tumors. Within GB, we performed an RNA-seq analysis between samples exhibiting the lowest and highest levels of acetylated H3 in the cohort; these results are in general concordance with the transcriptional changes obtained after histone deacetylase (HDAC) inhibition of GB-derived cultures that affected relevant genes in glioma biology and treatment (e.g., A2ML1, CD83, SLC17A7, TNFSF18). Overall, we identified a transcriptional signature linked to histone acetylation that was potentially associated with good prognosis, i.e., high overall survival and low rate of somatic mutations in epigenetically related genes in GB. Our study identifies lysine acetylation as a key defective histone modification in adult high-grade glioma, and offers novel insights regarding the use of HDAC inhibitors in therapy.

Verified
Journal Article
Open access
PDF file
ÁPÁlvaro Pejenaute
Álvaro Pejenaute
PMPaula Martín-Climent
Paula Martín-Climent
MRMaria Martinez Rubio
Maria Martinez Rubio
JSJesús Saborido-Gavilán
Jesús Saborido-Gavilán
NSNeira Sáinz
Neira Sáinz
MMMaria J. Moreno-Aliaga
Maria J. Moreno-Aliaga
The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) increases with age and obesity. The aim of this study was to characterize the transcriptomic changes in liver underlying the beneficial effects of docosahexaenoic acid (DHA) supplementation on MASLD progression in aged obese female mice. Two-month-old C57BL/6J female mice were fed ad libitum with high fat saturated diet (HFD, 45%) for 4 months. These diet-induced obese (DIO) mice were divided into two groups: the DIO group that continued with HFD and the DIO + DHA mice fed up to 18 months with the HFD containing a DHA-rich concentrate. High quality RNA from liver was used to perform RNA sequencing analysis. Further functional and clustering analyses of differentially expressed genes (DEGs) in liver between treatments revealed that DHA regulated processes related to lipid metabolic processes. DHA treatment also affects the PPAR signaling pathway and the regulation of inflammatory response. These data suggest that long-term DHA supplementation ameliorates MASLD progression in aged obese female mice by promoting transcriptomic changes in genes related to lipid metabolism and inflammatory response.

16 December 2025 in bioRxiv
Verified
Preprint
Open access
PMPaula Martín-Climent
Paula Martín-Climent
SMSamanta Ortuño Miquel
Samanta Ortuño Miquel
JGJuan F. Gallego-Serna
Juan F. Gallego-Serna
SMSilvia Martí-Martínez
Silvia Martí-Martínez
LVLuis M. Valor
Luis M. Valor
Transcriptional dysregulation is among the most prominent molecular alterations in Huntington’s disease (HD). It is not confined to brain but is also extended to peripheral tissues and cells, enabling minimally invasive screens aimed at identifying transcriptional surrogates of the health status in HD mutation carriers. Nonetheless, transcriptomics approaches have failed to identify consistent candidates from peripheral blood, probably due to the low impact of the HD mutation in the transcriptional profiles of circulating cells that can be masked by the high cellular complexity of this biofluid. In this study, we applied for the first time single-cell RNA-seq in peripheral blood mononuclear cells (PBMCs) to determine those cells that accumulate the most prominent gene expression changes as potential sources of reliable biomarkers. We observed both specific and common transcriptional alterations across different blood cell subtypes, justifying partial overlapping of our results with published bulk transcriptomics datasets. To relate these gene expression patterns with disease progression in the absence of a large cohort of patients, we examined selected candidates in a phenotypically characterized cohort of transgenic R6/1 mice. Of the tested genes, only the changes in the interferon related gene Irf7 in blood were correlated with motor coordination performance in mutant mice. Notably, this gene was significantly upregulated in the striatum of these animals. Overall, transcriptional-based changes in peripheral blood can be linked to HD although dissection of individual blood cells in combination with subsequent validation in mouse models emphasizes the challenges in obtaining clinically relevant biomarkers in HD.